Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of KSP-1007-05 with Meropenem in Healthy Adult Males
jRCT2071240121Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of KSP-1007-05 (6 arms), sponsored by Sumitomo Pharma. Primary endpoint: Safety and tolerability. Started Mar 2025; status: completed.
02
Drugs
KSP-1007-05
Beyond the preview
Go deeper on jRCT2071240121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240121.